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The relationship between surfactant-associated protein D polymorphisms and chronic obstructive pulmonary
disease risk remains controversial. This article is the first to systematically evaluate this relationship.
A comprehensive worldwide search was conducted for relevant literature on surfactant-associated protein D
gene mutations and chronic obstructive pulmonary disease risk prediction. Study quality was evaluated using
the Newcastle-Ottawa scale. After four genetic models (the allele, additive, recessive, and dominant models)
were identified, odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were applied in this
meta-analysis. The meta-analysis included 659 individuals in the case group and 597 in the control group. In the
Asian population, none of the four genetic models revealed any significant association between rs2243639
genotype and the risk of chronic obstructive pulmonary disease. In Caucasians, however, the recessive model
exhibited significant risk associated with rs2243639. Furthermore, there was a significant association between
rs721917 genotype and the risk of chronic obstructive pulmonary disease in the Asian population. In contrast,
none of the four gene models revealed any significant risk associated with this gene in the Caucasian popu-
lation. This meta-analysis suggests that rs2243639 is not related to the risk of chronic obstructive pulmonary
disease in the Asian population but is related to this risk in the Caucasian population. Regarding rs721917, the
T allele may increase the risk of chronic obstructive pulmonary disease in the Asian population.
KEYWORDS: Surfactant-Associated Protein D; Chronic Obstructive Pulmonary Disease; Genetic Polymorphism;
Meta-Analysis.
’ INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
preventable, treatable disease characterized by persistent
airflow limitation accompanied by gradual deterioration of
lung function and a series of abnormalities in mental and
physical functions (1). COPD imposes a heavy economic
burden on global public health resources. It is one of the
major causes of hospitalization and emergency care, and it
is also one of the leading causes of death worldwide (2,3).
Approximately 3.2 million people died in 2015 due to COPD
and related complications (4).
The pathogenesis of COPD is still not fully understood. It
is generally believed to be related to inflammation, protease-
antitrypsin imbalance, and oxidative stress stimulation. It is
widely believed that COPD is caused by both environmental
and genetic factors. In recent years, with the development of
genome-wide association study (GWAS) technology, increas-
ing numbers of COPD-related susceptibility genes have
been discovered, such as tumor necrosis factor-a (TNF- a),
transforming growth factor-b1 (TGF-b1), A disintegrin
and metalloproteinase 33 (ADAM33), superoxide dismutase
(SOD), alveolar surface-associated protein D (SP-D) and
other related susceptibility genes (5).
Alveolar surfactant-associated protein (SP) is an active sub-
stance synthesized and secreted by alveolar type II epithelial
cells. It is composed of phospholipids and a small amount of
protein, and it usually covers the alveolar surface to maintain
alveolar surface tension and promote the smooth progress
of pulmonary ventilation. It also has immunomodulatory and
anti-inflammatory effects (6). SP has four phenotypes, namely,
A, B, C and D. Among them, D plays a prominent role in host
immune regulation. A study confirmed that the expression
level of SP-D in the serum can be used as a biomarker for
the diagnosis of COPD (7).
Increasing studies have been performed to assess poly-
morphisms of the SP-D gene, but some controversies remain.
The data on SP-D single nucleotide polymorphisms (SNPs)
has primarily focused on rs2243639 and rs721917. Therefore,
this meta-analysis was performed to explore the relationship
between the abovementioned SNPs and the risk of develop-
ing COPD.
’ MATERIALS AND METHODS
Study identification
Scaling strategies. A comprehensive search was con-
ducted for relevant literature published by scholars world-
wide on SP-D gene mutations and COPD risk prediction.DOI: 10.6061/clinics/2019/e855
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The databases searched were the Wanfang Data Knowledge
Service Platform and the VIP Chinese Science and Technology
Periodical Database (VIP), the China National Knowledge
Infrastructure (CNKI), the China Dissertation Database,
PubMed, Embase, the Cochrane Library, and Web of Science.
The retrieval time was set from January 1, 1997, to September
30, 2018. The search terms were ‘‘surfactant-related protein D
gene’’ and ‘‘chronic obstructive pulmonary disease’’. The
results were limited to articles in English and Chinese. The
literature screening process is shown in Figure 1.
The inclusion criteria were as follows: 1) The article was
related to polymorphisms of the SP-D gene and the risk
of COPD, 2) the study was a case-control, cohort, or group
design study, 3) the inclusion and exclusion criteria of the
case and control groups in the study were clear, and the
experimental goals included were in line with the aim
of this meta-analysis, 4) there were complete experimental
data and results, 5) The case group and the control group
involved human subjects, and 6) the article was written in
English or Chinese.
The exclusion criteria were as follows: 1) duplicate report,
2) defects and poor-quality study design, 3) incomplete
data and unclear outcome effect, 4) flawed statistics and the
inability to extract relevant data, 5) animal experiments, and
6) non-Chinese- and English-language articles.
Data extraction
The two researchers independently screened the literature
to exclude the literature that did not meet the inclusion
criteria. Differences were resolved through group discussion.
Data were extracted independently according to the prede-
signed form, and the extracted data were cross-checked.
The following information was extracted from each study:
name of the first author, year of publication, race, definition
and source of the control and case groups, smoking status
in cases and controls, and the number of genotypes and
individual base pairs.
Quality assessment
The quality of the included literature was evaluated by
two independent researchers in strict accordance with the
Newcastle-Ottawa Scale (NOS) (8). The selectivity, compar-
ability and exposure of each article were assessed, and all six
documents included were of high quality. The literature
quality assessment is shown in Table 1.
Statistical methods
All data included in the literature were analyzed using
Stata MP13.0 (64-bit). At the same time, to reduce the
probability of type I errors (9), we performed multiple
pairwise comparisons of each genotype and used the
following four models: 1. The allele model (A vs B), 2.
The additive model (AA vs BB), 3. The recessive model (AA
vs AB+BB), and 4. The dominant model (AA+AB vs BB)
(10). At the same time, a test was performed on the
included data to further reduce sampling bias by deter-
mining if the data were in Hardy-Weinberg equilibrium
(HWE) (11). In addition, the minor allele frequency (MAF)
was calculated. Heterogeneity tests were performed on all
included data. If the heterogeneity was not significant
(p40.05, I2o50%), the M-H fixed effect model was used
to calculate the odds ratio (OR) and its 95% confidence
interval (CI). If the heterogeneity was significant (po0.05,
I2450%), the OR and its 95% CI were randomly calcula-
ted using the M-H heterogeneity random effects model. At
the same time, subgroup analyses were performed using
different ethnic classifications. All included articles were
Figure 1 - Flow chart of study selection based on the inclusion
criteria.
Table 1 - Quality assessment of the studies included in the meta-analysis.
First author Selection Comparability Exposure Total score
1 2 3 4 1 2 1 2 3
Ou et al. [12] $ $ - $ $ $ $ $ $ 8
Shakoori et al. [13] $ $ $ $ $ - $ $ $ 7
Issac et al. [14] $ $ - $ $ $ $ $ $ 8
Fakih et al. [15] $ $ $ $ $ $ $ $ $ 8
Wu [16] $ $ - $ $ $ $ $ $ 8
Wu [17] $ $ - $ $ - $ $ $ 7
Selection: 1. Whether the case is sufficiently defined (if some independent validation was required, one star); 2. Whether the case is representative (if yes,
one star); 3. The choice of the control (if they were community controls, one star); 4. Definition of control (if they had no history and new occurrence, one
star). Comparability: 1. The study controlled for the influence of age (if yes, one star); 2. The study also controlled other important confounding factors
such as gender and smoking history (if yes, one star). Exposure: 1. Determination of exposure (if by reliable method, one star); 2. Same method of
ascertainment for cases and controls (if yes, one star); 3. No response rate (if the two groups had the same nonresponse rate, one star).
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analyzed for bias using the Egger method. If po0.05,
publication bias was considered. The risk of bias is shown
in Table 2. The gene distribution of each model is shown
in Table 3.
’ RESULTS
Study characteristics
In total, 420 articles were initially collected, and 380
articles that did not meet the inclusion criteria were then
excluded. Thirty articles that had defects in experimental
design, case-control criteria, and other aspects were excluded
based on the information in the abstract. After reading the
full texts of the remaining articles, 4 additional articles were
excluded. In total, 6 articles (12-17) were included, with
2 written in Chinese and 4 in English. The meta-analysis
included 9 groups in case-control studies, including 659
individuals in the case group and 597 in the control group,
for a total of 1256 individuals. Two sets of case-control studies
were from Europe, and the rest were from Asia. The two SNPs
investigated were rs2243639 and rs721917. The characteristics
of the included studies are shown in Table 4.
Association between SPD gene polymorphisms and
COPD
The total population analysis of rs2243639 with the
random effects model revealed heterogeneity in the allelic
model (OR 0.99; 95% CI 0.69-1.43; I2=55.6%) and recessive
model (OR 0.90; 95% CI 0.53- 1.53; I2=61.3%). When using
the fixed effect model, there was low heterogeneity in the
additive model (OR 1.06; 95% CI 0.58-1.96; I2= 12.9%) and
the dominant model (OR 1.19; 95% CI 0.68-2.07; I2=0%). In
the subgroup analysis in the Asian population, the allelic
model (OR 1.14; 95% CI 0.87-1.15; I2=18.8%), additive
model (OR 1.36; 95% CI 0.69-2.68; I2=18.8%), recessive
model (OR 1.13; 95% CI 0.76-1.69; I2=28.1%), and dominant
model (OR 1.36; 95% CI 0.75-2.49; I2=0%) revealed no
association. However, for Caucasians, the recessive model
was significantly different (OR 0.37; 95% CI 0.14-0.96;
I2=0%) (Figure 2) (Table 5).
For the total population analysis of rs721917, when using a
fixed effect model, the allelic model (OR 1.39; 95% CI 1.18-
1.65; I2=0%), additive model (OR 1.96; 95% CI 1.34-2.89;
I2=0%), recessive model (OR 1.42; 95% CI 1.06-1.91; I2=0%),
and dominant model (OR 1.78; 95% CI 1.33-2.38; I2=0%) had
low heterogeneity. In the subgroup analysis, in the Asian
population, there was low heterogeneity in the allele model
(OR 1.44; 95% CI 1.20-1.73; I2=0%), additive model (OR 2.10;
95% CI 1.38-3.21; I2=0%), recessive model (OR 1.48; 95% CI
1.07-2.05; I2=0%), and dominant model (OR 1.86; 95% CI
1.37-2.54; I2=0%). There were no significant differences in the
risk of COPD in the Caucasian population in the four gene
models (Figure 3) (Table 5).
Publication bias
Publication bias was assessed using Egger’s test. We
detected significant publication bias in the additive model
for rs2243639 in the total population only. There was no
significant evidence of publication bias in the other genetic
models (Table 2).
’ DISCUSSION
Previous studies have shown that smoking is a risk factor
for COPD development but that genetic factors also con-
tribute (18-25). Some researchers have studied the association
between SPD polymorphisms and COPD susceptibility; this
association was first reported in the Mexican population in
2001 (26). Some studies have reported that the SPD gene
plays an important role in the development of asthma (15),
silicosis (27) and tuberculosis (28). However, there is still
controversy concerning the genetic associations of SPD with
Table 2 - Egger’s linear regression test to measure funnel plot asymmetry.
SNP Group P
A vs B AA vs BB AA vs AB+BB AA+AB vs BB
rs2243639 All (n=4) 0.610 0.425 0.040 0.620
Asian (n=3) 0.689 0.899 0.280 0.677
Caucasian (N=1) - - - -
rs721917 All (n=5) 0.375 0.384 0.715 0.634
Asian (n=4) 0.457 0.221 0.828 0.319
Caucasian (N=1) - - - -
Table 3 - Frequency of the rs2243639 and rs721917 polymorphisms in different populations.
SNP Author Race Case group Control group HWE (p value) MAF
AA AB BB AA AB BB
rs2243639 Wu [16] Asian 87 27 3 89 24 4 0.16 0.14
Ou et al. [12] Asian 133 53 6 76 45 7 0.92 0.19
Shakoori et al. [13] Asian 16 81 14 15 61 13 o0.05 0.49
Issac et al. [14] Caucasian 18 36 9 13 10 2 0.97 0.39
rs721917 Ou et al. [12] Asian 86 81 25 43 62 22 0.38 0.37
Shakoori et al. [13] Asian 18 56 6 16 51 18 o0.05 0.47
Fakih et al. [15] Caucasian 17 35 10 28 64 23 0.22 0.46
Wu [16] Asian 18 66 33 9 60 48 0.10 0.38
Wu [17] Asian 15 61 34 14 42 50 0.28 0.37
HWE: Hardy-Weinberg equilibrium
MAF: Minimum allele frequency
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COPD at present. Therefore, we attempted to collect the
articles related to the genetic associations of SPD with COPD
to conduct a comprehensive meta-analysis to assess this
relationship accurately. Furthermore, in Asian popula-
tions, the results of the analysis of the four genotypes all
indicated significant differences between the case group
and the control group and low heterogeneity of rs721917.
Therefore, we conclude that in Asian populations, there is
a strong correlation between SPD and the risk of develop-
ing COPD.
This meta-analysis showed that there was no statistically
significant association between the polymorphisms of
rs2243639 and the risk of COPD in the Asian population.
There were three genotypes (GG, GA, and AA) in the
polymorphic locus of rs2243639 in the exon 5 region of the
SP-D gene. For the Asian population, the rs2243639 poly-
morphism was found in both patients with COPD and
healthy individuals. There was no significant difference in
the risk of COPD between those with the polymorphism and
those without. Surprisingly, subgroup analysis revealed that
SPD polymorphisms, particularly the G allele, increased the
risk of susceptibility to COPD in Caucasians. Nevertheless,
only one genetic model was significantly different, the
sample size of the Caucasian population was small, and
only one group was included in the meta-analysis. There-
fore, caution should be taken in the interpretation of the
research results, and a larger sample size and well-designed
investigation will be necessary to confirm the conclusion of
this study.
For rs721917, the rs721917 polymorphism and the risk of
COPD were significantly associated in the Asian population
but not the Caucasian population. In the SP-D exon 1 region,
there are three rs721917 genotypes (TT, TC, CC). The inclu-
ded studies and this meta-analysis showed that compared
to the C allele, the T allele may increase the risk of COPD in
the Asian population but not in the Caucasian population.
Foreman et al. (29) demonstrated that the rs721917 poly-
morphism was not associated with the risk of COPD in a
controlled trial of 823 patients with COPD and 810 healthy
smokers in a Norwegian population. Interestingly, regarding
the Asian population, Ishii et al. (30) also verified that the C
allele of rs721917 is a risk genotype for COPD in the Japanese
population. The reason for these reports may be as follows.
(1) Due to differences in genetic background and gene
distribution proceeding from the influences of region, race
and environment, the results may be inconsistent. (2) Multi-
gene interactions may also contribute; COPD results from the
joint action of multiple genes and the environment. Other
COPD-related genes may affect the experimental results. (3)
Clinical phenotype inconsistency may contribute; although
the sample size of Foreman et al. (29) was large enough to
achieve high statistical power, the clinical phenotype in focus
involved patients with bilateral lung emphysema, and the
estimated FEV1 value was less than 45%, whereas the other
reports included COPD patients whose estimated FEV1
values were greater than 45%. (4) Different groups and
inclusion criteria among different studies may lead to
different results.
This meta-analysis had some deficiencies. First, the
number of included studies was relatively small, and the
included studies were all written in Chinese or English.
Useful studies in other languages may have been missed.
At the same time, papers from academic conferences and
other documents were not included. Second, the analysis ofTa
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Figure 2 - Forest plots of the association between the rs2243639 polymorphism and the risk of COPD (A, allelic model; B, additive
model; C, recessive model; D, dominant model).
Table 5 - Results of the meta-analysis for primary SPD SNP polymorphisms associated with the risk of COPD.
SNP Gene model Group p OR (95% CI) I2 (%) Analysis model
rs2243639 A vs B Asian (N=3) 0.337 1.14 (0.87-1.51) 18.8 R
Caucasian (N=1) 0.070 0.52 (0.25-1.06) - R
all (N=4) 0.976 0.99 (0.69-2.68) 55.6 R
AA vs BB Asian (N=3) 0.378 1.36 (0.69-2.69) 0 F
Caucasian (N=1) 0.172 0.31 (0.06-1.67) - F
all (N=4) 0.846 1.06 (0.58-1.96) 12.9 F
AA vs AB+BB Asian (N=3) 0.544 1.13 (0.76-1.69) 28.1 R
Caucasian (N=1) 0.041 0.37 (0.14-0.96) - R
all (N=4) 0.692 0.90 (0.53-1.53) 61.3 R
AA+AB vs BB Asian (N=3) 0.312 1.36 (0.75-2.49) 0 F
Caucasian (N=1) 0.428 0.52 (0.10-2.60) - F
all (N=4) 0.539 1.19 (0.68-2.07) 0 F
rs721917 A vs B Asian (N=4) o0.001 1.44 (1.20-1.73) 0 F
Caucasian (N=1) 0.532 1.15 (0.74-1.78) - F
all (N=5) o0.001 1.39 (1.18-1.65) 0 F
AA vs BB Asian (N=4) 0.001 2.10 (1.38-3.21) 0 F
Caucasian (N=1) 0.494 1.40 (0.54-3.63) - F
all (N=5) 0.001 1.96 (1.34-2.89) 0 F
AA vs AB+BB Asian (N=4) 0.017 1.48 (1.07-2.05) 0 F
Caucasian (N=1) 0.655 1.17 (0.58-2.37) - F
all (N=5) 0.018 1.42 (1.06-1.91) 0 F
AA+AB vs BB Asian (N=4) o0.001 1.86 (1.37-2.54) 0 F
Caucasian (N=1) 0.529 1.30 (0.57-2.94) - F
all (N=5) o0.001 1.78 (1.33-2.38) 0 F
OR, odds ratio; CI, confidence interval; R, random effects model; F, fixed effects model.
5
CLINICS 2019;74:e855 A meta-analysis of gene polymorphism and COPD
Liao Y et al.
publication bias revealed bias in the recessive model of the
rs2243639 polymorphism, and the HWE test showed that
some of the included samples did not adhere to the Hardy–
Weinberg principle. Third, data from Caucasian populations
were scarce. At the same time, the proportion of Chinese
individuals among those from Asian populations was
relatively high, which had an impact on the conclusions.
Fourth, in some of the included studies, there were sta-
tistically significant differences in smoking status between
the case group and the control group, which also affected
the results.
According to the results of the current meta-analysis,
the rs2243639 polymorphism was associated with the risk
of COPD in Caucasian populations but not in Asian
populations. Among Asians, compared with the C allele
for rs721917, the T allele may increase the risk of COPD.
Due to the limitations of the quality and quantity of the
articles included in the present meta-analysis, the conclu-
sions obtained need to be confirmed by more uniform
case–control or cohort studies.
’ ACKNOWLEDGMENTS
We express our thanks for the English editing services of American Journal
Experts.
’ AUTHOR CONTRIBUTIONS
Liao Y was responsible for the topic selection and manuscript writing.
Huang CL was responsible for the manuscript revision. Wang JR was
responsible for the quality assessment and analysis. Fan XM was responsible
for the funding, design, writing and control of the project.
’ REFERENCES
1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau
J, et al. Global strategy for the diagnosis, management and prevention
of chronic obstructive lung disease 2017 report: GOLD executive
summary. Respirology. 2017;22(3):575-601, https://doi.org/10.1111/
resp.13012.
2. Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M.
The global economic burden of asthma and chronic obstructive pul-
monary disease. Int J Tuberc Lung Dis. 2016;20(1):11-23, https://doi.org/
10.5588/ijtld.15.0472.
3. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health
Epidemiol Genom. 2018;3:e4, https://doi.org/10.1017/gheg.2018.1.
4. Global, regional, and national deaths, prevalence, disability-adjusted life
years, and years lived with disability for chronic obstructive pulmonary
disease and asthma, 1990-2015: a systematic analysis for the Global
Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706,
https://doi.org/10.1016/S2213-2600(17)30293-X.
5. Hu D, Bao W, Sun Y, Yang Z. Research progress of susceptible genes for
chronic obstructive pulmonary disease. Chinese Elderly Health Care
Medicine. 2016;14(6):3-6.
6. Hartl D, Griese M. Surfactant protein D in human lung diseases. Eur J
Clin Invest. 2006;36(6):423-35, https://doi.org/10.1111/j.1365-2362.2006.
01648.x.
Figure 3 - Forest plots of the association between the rs721917 polymorphism and the risk of COPD (A, allelic model; B, additive model;
C, recessive model; D, dominant model).
6
A meta-analysis of gene polymorphism and COPD
Liao Y et al.
CLINICS 2019;74:e855
7. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P,
et al. Inflammatory biomarkers improve clinical prediction of
mortality in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med. 2012;185(10):1065-72, https://doi.org/10.1164/rccm.
201110-1792OC.
8. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al.
The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-
randomised studies in meta-analyses 2003 Available from: http://www.
ohri.ca/programs/clinical_epidemiology/oxford.asp.
9. Luo J, Leng W. System evaluation/meta analysis theory and practice.
Chinese J Evid Base Cardiovasc Med. 2013;5(2):508-12.
10. Lewis CM, Knight J. Introduction to genetic association studies. Cold
Spring Harb Protoc. 2012;2012(3):297-306, https://doi.org/10.1101/pdb.
top068163.
11. Xu C, Liu T, Xiantao Z. Meta-analysis series fourteen: meta analysis of
Stata’s achievement of single nucleotide polymorphisms. Chinese J Evid
Base Cardiovasc Med. 2013;5(5):445-8.
12. Ou CY, Chen CZ, Hsiue TR, Lin SH, Wang JY. Genetic variants of
pulmonary SP-D predict disease outcome of COPD in a Chinese
population. Respirology. 2015;20(2):296-303, https://doi.org/10.1111/
resp.12427.
13. Shakoori TA, Sin DD, Bokhari SN, Ghafoor F, Shakoori AR. SP-D poly-
morphisms and the risk of COPD. Dis Markers. 2012;33(2):91-100,
https://doi.org/10.1155/2012/802145.
14. Issac MS, Ashur W, Mousa H. Genetic polymorphisms of surfactant
protein D rs2243639, Interleukin (IL)-1b rs16944 and IL-1RN rs2234663
in chronic obstructive pulmonary disease, healthy smokers, and non-
smokers. Mol Diagn Ther. 2014;18(3):343-54, https://doi.org/10.1007/
s40291-014-0084-5.
15. Fakih D, Akiki Z, Junker K, Medlej-Hashim M, Waked M, Salameh P, et al.
Surfactant protein D multimerization and gene polymorphism in COPD
and asthma. Respirology. 2018;23(3):298-305, https://doi.org/10.1111/
resp.13193.
16. Wu B. Study on polymorphism of SP-d gene and susceptibility to COPD
[dissertation]. Qingdao: Qingdao University; 2015.
17. Wu Y. Genetic polymorphism of SP-D gene and susceptibility to chronic
obstructive pulmonary disease in Han population in Guangdong [dis-
sertation]. Guangzhou: Guangzhou Medical University; 2016.
18. Cui K, Ge XY, Ma HL. Association of the TNF-a+489 G/A poly-
morphism with chronic obstructive pulmonary disease risk in Asians:
meta-analysis. Genet Mol Res. 2015;14(2):5210-20, https://doi.org/
10.4238/2015.May.18.12.
19. Cui K, Ge XY, Ma HL. Association of -238G/A and -863C/A poly-
morphisms in the TNF-a gene with chronic obstructive pulmonary
disease based on a meta-analysis. Genet Mol Res. 2013;12(4):4981-9,
https://doi.org/10.4238/2013.October.24.10.
20. Guo Y, Gong Y, Pan C, Qian Y, Shi G, Cheng Q, et al. Association of
genetic polymorphisms with chronic obstructive pulmonary disease in
the Chinese Han population: a case-control study. BMC Med Genomics.
2012;5:64, https://doi.org/10.1186/1755-8794-5-64.
21. Wang YS, Liu L, Xu XY, Wang JL, Zhou H, Li TL, et al. Association of
interleukin-1b -511C/T promoter polymorphism with COPD risk: a meta-
analysis. Genet Mol Res. 2015;14(2):4477-84, https://doi.org/10.4238/
2015.May.4.5.
22. Jiang S, Yang ZH, Chen YY, He Z, Zhou Y, Gao Y, et al. MMP-9 genetic
polymorphism may confer susceptibility to COPD. Genet Mol Res.
2016;15(2), https://doi.org/10.4238/gmr.15026272.
23. Hu G, Shi Z, Hu J, Zou G, Peng G, Ran P. Association between poly-
morphisms of microsomal epoxide hydrolase and COPD: results from
meta-analyses. Respirology. 2008;13(6):837-50, https://doi.org/10.1111/
j.1440-1843.2008.01356.x.
24. Lee J, Nordestgaard BG, Dahl M. EPHX1 polymorphisms, COPD and
asthma in 47,000 individuals and in meta-analysis. Eur Respir J. 2011;
37(1):18-25, https://doi.org/10.1183/09031936.00012110.
25. Yan F, Chen C, Jing J, Li W, Shen H, Wang X. Association between
polymorphism of glutathione S-transferase P1 and chronic obstructive
pulmonary disease: a meta-analysis. Respir Med. 2010;104(4):473-80,
https://doi.org/10.1016/j.rmed.2010.01.009.
26. Guo X, Lin HM, Lin Z, Montano M, Sansores R, Wang G, et al. Surfactant
protein gene A, B, and D marker alleles in chronic obstructive pulmonary
disease of a Mexican population. Eur Respir J. 2001;18(3):482-90, https://
doi.org/10.1183/09031936.01.00043401.
27. Wu CW, Zhang XF, Liu W, Wang HL, Hao XH, Guo ZY, et al. [Association
of surfactant protein D gene polymorphisms at rs3088308 and rs721917
with susceptibility to silicosis]. Nan Fang Yi Ke Da Xue Xue Bao. 2016;
36(7):1004-7.
28. Hsieh MH, Ou CY, Hsieh WY, Kao HF, Lee SW, Wang JY, et al.
Functional analysis of genetic variations in surfactant protein D
in mycobacterial infection and their association with tuberculosis. Front
Immunol. 2018;9:1543, https://doi.org/10.3389/fimmu.2018.01543.
29. Foreman MG, Kong X, DeMeo DL, Pillai SG, Hersh CP, Bakke P, et al.
Polymorphisms in surfactant protein-D are associated with chronic
obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2011;44(3):316-
22, https://doi.org/10.1165/rcmb.2009-0360OC.
30. Ishii T, Hagiwara K, Ikeda S, Arai T, Mieno MN, Kumasaka T, et al.
Association between genetic variations in surfactant protein d and emphy-
sema, interstitial pneumonia, and lung cancer in a Japanese population.
COPD. 2012;9(4):409-16, https://doi.org/10.3109/15412555.2012.676110.
7
CLINICS 2019;74:e855 A meta-analysis of gene polymorphism and COPD
Liao Y et al.
